annual CFF:
$140.66M+$151.52M(+1395.62%)Summary
- As of today (July 1, 2025), CPRX annual cash flow from financing activities is $140.66 million, with the most recent change of +$151.52 million (+1395.62%) on December 31, 2024.
- During the last 3 years, CPRX annual CFF has risen by +$148.81 million (+1827.43%).
- CPRX annual CFF is now at all-time high.
Performance
CPRX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$3.06M-$1.37M(-30.97%)Summary
- As of today (July 1, 2025), CPRX quarterly cash flow from financing activities is $3.06 million, with the most recent change of -$1.37 million (-30.97%) on March 31, 2025.
- Over the past year, CPRX quarterly CFF has dropped by -$137.99 million (-97.83%).
- CPRX quarterly CFF is now -97.83% below its all-time high of $141.05 million, reached on March 31, 2024.
Performance
CPRX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$2.68M-$137.99M(-98.10%)Summary
- As of today (July 1, 2025), CPRX TTM cash flow from financing activities is $2.68 million, with the most recent change of -$137.99 million (-98.10%) on March 31, 2025.
- Over the past year, CPRX TTM CFF has dropped by -$127.37 million (-97.94%).
- CPRX TTM CFF is now -98.10% below its all-time high of $140.66 million, reached on December 31, 2024.
Performance
CPRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CPRX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1395.6% | -97.8% | -97.9% |
| 3 y3 years | +1827.4% | +297.3% | +127.1% |
| 5 y5 years | +10000.0% | +10000.0% | +198.6% |
CPRX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +1395.6% | -97.8% | +130.2% | -98.1% | +124.7% |
| 5 y | 5-year | at high | +1395.6% | -97.8% | +130.2% | -98.1% | +124.7% |
| alltime | all time | at high | +1395.6% | -97.8% | +130.2% | -98.1% | +124.7% |
CPRX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $3.06M(-31.0%) | $2.68M(-98.1%) |
| Dec 2024 | $140.66M(-1395.6%) | $4.43M(-174.2%) | $140.66M(+3.8%) |
| Sep 2024 | - | -$5.97M(-616.3%) | $135.57M(+3.2%) |
| Jun 2024 | - | $1.16M(-99.2%) | $131.41M(+1.1%) |
| Mar 2024 | - | $141.05M(<-9900.0%) | $130.04M(-1297.8%) |
| Dec 2023 | -$10.86M(-740.9%) | -$665.00K(-93.4%) | -$10.86M(+36.8%) |
| Sep 2023 | - | -$10.13M(+4632.2%) | -$7.94M(-228.6%) |
| Jun 2023 | - | -$214.00K(-243.6%) | $6.17M(+81.9%) |
| Mar 2023 | - | $149.00K(-93.4%) | $3.39M(+100.4%) |
| Dec 2022 | $1.69M(-120.8%) | $2.25M(-43.4%) | $1.69M(-154.9%) |
| Sep 2022 | - | $3.98M(-233.2%) | -$3.08M(-66.3%) |
| Jun 2022 | - | -$2.99M(+92.9%) | -$9.17M(-7.2%) |
| Mar 2022 | - | -$1.55M(-38.6%) | -$9.88M(+21.4%) |
| Dec 2021 | -$8.14M(-1260.0%) | -$2.53M(+20.4%) | -$8.14M(+45.6%) |
| Sep 2021 | - | -$2.10M(-43.4%) | -$5.59M(+94.2%) |
| Jun 2021 | - | -$3.71M(-2071.8%) | -$2.88M(-433.2%) |
| Mar 2021 | - | $188.00K(+623.1%) | $864.00K(+23.1%) |
| Dec 2020 | $702.00K(-37.1%) | $26.00K(-95.8%) | $702.00K(-44.0%) |
| Sep 2020 | - | $614.00K(+1605.6%) | $1.25M(+39.9%) |
| Jun 2020 | - | $36.00K(+38.5%) | $896.10K(-14.9%) |
| Mar 2020 | - | $26.00K(-95.5%) | $1.05M(-5.7%) |
| Dec 2019 | $1.12M(+280.8%) | $578.00K(+125.7%) | $1.12M(+61.9%) |
| Sep 2019 | - | $256.10K(+33.0%) | $689.40K(+28.2%) |
| Jun 2019 | - | $192.50K(+115.6%) | $537.80K(+53.9%) |
| Mar 2019 | - | $89.30K(-41.1%) | $349.40K(+19.2%) |
| Dec 2018 | $293.10K(-99.5%) | $151.50K(+45.0%) | $293.10K(-99.5%) |
| Sep 2018 | - | $104.50K(+2448.8%) | $54.28M(-2.3%) |
| Jun 2018 | - | $4100.00(-87.6%) | $55.58M(-3.1%) |
| Mar 2018 | - | $33.00K(-99.9%) | $57.38M(+0.1%) |
| Dec 2017 | $57.35M(>+9900.0%) | $54.14M(+3745.2%) | $57.35M(+1641.3%) |
| Sep 2017 | - | $1.41M(-22.0%) | $3.29M(+74.7%) |
| Jun 2017 | - | $1.81M(>+9900.0%) | $1.89M(+2248.3%) |
| Mar 2017 | - | $0.00(-100.0%) | $80.30K(+16.4%) |
| Dec 2016 | $69.00K(-99.8%) | $80.30K(>+9900.0%) | $69.00K(+27.5%) |
| Sep 2016 | - | $0.00(0.0%) | $54.10K(-94.4%) |
| Jun 2016 | - | $0.00(-100.0%) | $970.70K(-10.4%) |
| Mar 2016 | - | -$11.30K(-117.3%) | $1.08M(-97.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | $37.16M(+30.1%) | $65.40K(-92.9%) | $37.16M(-4.5%) |
| Sep 2015 | - | $916.60K(+711.2%) | $38.92M(+2.4%) |
| Jun 2015 | - | $113.00K(-99.7%) | $38.00M(-41.2%) |
| Mar 2015 | - | $36.06M(+1879.4%) | $64.61M(+126.2%) |
| Dec 2014 | $28.56M(+57.1%) | $1.82M(>+9900.0%) | $28.56M(+6.1%) |
| Sep 2014 | - | $0.00(-100.0%) | $26.93M(-40.0%) |
| Jun 2014 | - | $26.73M(>+9900.0%) | $44.90M(+146.8%) |
| Mar 2014 | - | $16.50K(-91.3%) | $18.20M(+0.1%) |
| Dec 2013 | $18.18M(+24.7%) | $189.80K(-98.9%) | $18.18M(-21.2%) |
| Sep 2013 | - | $17.97M(>+9900.0%) | $23.07M(+116.3%) |
| Jun 2013 | - | $23.50K(>+9900.0%) | $10.67M(-26.8%) |
| Mar 2013 | - | $0.00(-100.0%) | $14.58M(0.0%) |
| Dec 2012 | $14.58M(+163.1%) | $5.08M(-8.6%) | $14.58M(+13.8%) |
| Sep 2012 | - | $5.56M(+41.2%) | $12.81M(+76.7%) |
| Jun 2012 | - | $3.94M(>+9900.0%) | $7.25M(+118.8%) |
| Mar 2012 | - | $0.00(-100.0%) | $3.31M(-40.2%) |
| Dec 2011 | $5.54M(+280.6%) | $3.31M(>+9900.0%) | $5.54M(+148.7%) |
| Sep 2011 | - | $0.00(0.0%) | $2.23M(-39.5%) |
| Jun 2011 | - | $0.00(-100.0%) | $3.68M(0.0%) |
| Mar 2011 | - | $2.23M(>+9900.0%) | $3.68M(+153.0%) |
| Dec 2010 | $1.46M(-60.6%) | $0.00(-100.0%) | $1.46M(-71.7%) |
| Sep 2010 | - | $1.46M(>+9900.0%) | $5.15M(+39.4%) |
| Jun 2010 | - | $0.00(0.0%) | $3.70M(0.0%) |
| Mar 2010 | - | $0.00(-100.0%) | $3.70M(0.0%) |
| Dec 2009 | $3.70M(-9.5%) | $3.70M(>+9900.0%) | $3.70M(-1127.0%) |
| Sep 2009 | - | $0.00(-100.0%) | -$360.10K(-108.8%) |
| Dec 2008 | $4.08M(>+9900.0%) | -$360.10K(-108.1%) | $4.08M(-8.1%) |
| Sep 2008 | - | $4.46M(<-9900.0%) | $4.44M(<-9900.0%) |
| Jun 2008 | - | -$17.00K(+750.0%) | -$19.00K(+850.0%) |
| Mar 2008 | - | -$2000.00(<-9900.0%) | -$2000.00(<-9900.0%) |
| Dec 2007 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2007 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2007 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2007 | - | $0.00 | $0.00 |
| Dec 2006 | $20.86M(+1893.6%) | - | - |
| Dec 2005 | $1.05M(>+9900.0%) | - | - |
| Dec 2004 | $0.00 | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual CFF year-on-year change?
- What is Catalyst Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly CFF year-on-year change?
- What is Catalyst Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM CFF year-on-year change?
What is Catalyst Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of CPRX is $140.66M
What is the all time high annual CFF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual cash flow from financing activities is $140.66M
What is Catalyst Pharmaceuticals annual CFF year-on-year change?
Over the past year, CPRX annual cash flow from financing activities has changed by +$151.52M (+1395.62%)
What is Catalyst Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of CPRX is $3.06M
What is the all time high quarterly CFF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly cash flow from financing activities is $141.05M
What is Catalyst Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, CPRX quarterly cash flow from financing activities has changed by -$137.99M (-97.83%)
What is Catalyst Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of CPRX is $2.68M
What is the all time high TTM CFF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM cash flow from financing activities is $140.66M
What is Catalyst Pharmaceuticals TTM CFF year-on-year change?
Over the past year, CPRX TTM cash flow from financing activities has changed by -$127.37M (-97.94%)